CSBR Financials

Income Statement
MetricQ1 2027Q4 2026Q4 2026Q3 2026Q3 2026
Revenue
15.2M
+10.1%
13.8M
+0.0%
13.8M
-16.5%
16.6M
+0.0%
16.6M
Cost of Revenue
7.5M
+10.6%
6.8M
+0.0%
6.8M
-22.9%
8.8M
+0.0%
8.8M
Gross Profit
7.7M
+9.6%
7.0M
+0.0%
7.0M
-9.1%
7.7M
+0.0%
7.7M
Operating Expenses
8.1M
+7.4%
7.5M
+0.0%
7.5M
-4.6%
7.9M
+0.0%
7.9M
R&D
2.3M
+10.8%
2.1M
+0.0%
2.1M
-6.9%
2.3M
+0.0%
2.3M
SG&A
5.8M
+6.1%
5.4M
+0.0%
5.4M
-3.7%
5.6M
+0.0%
5.6M
Operating Income
-409000
+21.5%
-521000
+0.0%
-521000
-178.6%
-187000
+0.0%
-187000
EBITDA
-95000
+52.5%
-200000
+0.0%
-200000
-229.9%
154.0K
+0.0%
154.0K
Net Income
-426000
+36.1%
-667000
+0.0%
-667000
-139.1%
-279000
+0.0%
-279000
EPS (Basic)
$-0.03
+40.0%
$-0.05
+0.0%
$-0.05
-150.0%
$-0.02
+0.0%
$-0.02
EPS (Diluted)
$-0.03
+40.0%
$-0.05
+0.0%
$-0.05
-150.0%
$-0.02
+0.0%
$-0.02
Shares (Diluted)
13.9M
+5.3%
13.2M
+0.0%
13.2M
-5.0%
13.9M
+0.0%
13.9M
Champions Oncology (CSBR) โ€” Financials